Lin Y T, Wu B N, Wu J R, Lo Y C, Chen L C, Chen I J
Department of Cardiovascular Surgery, Kaohsiung Medical College, Taiwan, R.O.C.
J Cardiovasc Pharmacol. 1996 Jul;28(1):149-57. doi: 10.1097/00005344-199607000-00022.
The ultra-short-acting and vasorelaxant beta 1-adrenoceptor blocking activities of vasomolol, a guaiacoxypropanolamine derivative of vanillic acid ethyl ester, were studied. Vasomolol (0.5, 1.0, 3.0 mg/kg intravenously, i.v.) produced a dose-dependent bradycardia response and demonstrated particularly a hypotensive action with an ultra-short-acting property in pentobarbital-anesthetized normotensive rats. Vasomolol's steady state of beta-blockade was attained < or = 10 min after initial infusion, and a rapid recovery from blockade occurred after discontinuation of the infusion, although intravenous infusion of vasomolol (300 micrograms/kg/min) could not inhibit pressor responses induced by (-)phenylephrine (10 micrograms/kg i.v.). In isolated rat thoracic aorta, vasomolol (1-10 microM) inhibited vascular smooth muscle contractions induced by both (-)phenylephrine (10(-5) M) and high K+ (75 mM) concentration dependently. This inhibitory effect of vasomolol was more sensitive on K(+)-induced than on (-)phenylephrine-induced contractions, suggesting that the block of Ca2+ influx may involve the major mechanism of vasorelaxation. In isolated guinea pig tissues, vasomolol (0.01-10 microM) antagonized the (-)isoproterenol (ISO)-induced positive inotropic and chronotropic effects of the atria and tracheal relaxation responses in a concentration-dependent manner. The parallel shift to the right of the concentration-response curve of (-)ISO suggested that vasomolol was a beta-adrenoceptor competitive antagonist. The effect of vasomolol was more potent on atria than on tracheal tissues, indicating that it possesses beta 1-adrenoceptor selectivity. In addition, vasomolol did not show intrinsic sympathomimetic activity (ISA). Moreover, the binding characteristics of vasomolol were evaluated in [3H]dihydroalprenolol ([3H]DHA) binding to porcine ventricular membranes. Vasomolol was an ultra-short-acting and highly selective beta 1-adrenoceptor antagonist with vasorelaxant activity and is devoid of ISA.
研究了香草酸乙酯的愈创木酚丙醇胺衍生物——血管莫洛尔的超短效和血管舒张β1 - 肾上腺素能受体阻断活性。血管莫洛尔(静脉注射0.5、1.0、3.0mg/kg)在戊巴比妥麻醉的正常血压大鼠中产生剂量依赖性心动过缓反应,尤其表现出具有超短效特性的降压作用。血管莫洛尔在初始输注后≤10分钟达到β受体阻滞的稳态,输注停止后阻滞迅速恢复,尽管静脉输注血管莫洛尔(300μg/kg/min)不能抑制(-)去氧肾上腺素(静脉注射10μg/kg)诱导的升压反应。在离体大鼠胸主动脉中,血管莫洛尔(1 - 10μM)浓度依赖性地抑制(-)去氧肾上腺素(10⁻⁵M)和高钾(75mM)诱导的血管平滑肌收缩。血管莫洛尔对钾离子诱导的收缩的抑制作用比对(-)去氧肾上腺素诱导的收缩更敏感,表明钙内流的阻断可能涉及血管舒张的主要机制。在离体豚鼠组织中,血管莫洛尔(0.01 - 10μM)以浓度依赖性方式拮抗(-)异丙肾上腺素(ISO)诱导的心房正性肌力和变时作用以及气管舒张反应。(-)ISO浓度 - 反应曲线向右平行移动表明血管莫洛尔是一种β - 肾上腺素能受体竞争性拮抗剂。血管莫洛尔对心房的作用比对气管组织更强,表明它具有β1 - 肾上腺素能受体选择性。此外,血管莫洛尔未表现出内在拟交感活性(ISA)。此外,在[³H]二氢阿普洛尔([³H]DHA)与猪心室膜结合实验中评估了血管莫洛尔的结合特性。血管莫洛尔是一种具有血管舒张活性的超短效且高度选择性的β1 - 肾上腺素能拮抗剂,且无ISA。